PATENT CLAIM ANALYSIS

Application Number: 15970933
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["424", "048000"]

Abstract:
A new indication for the Warfarin family of drugs is described. In patients suffering from chronic periodontitis, continued systemic medication with Warfarin causes a significant reduction in their chronic periodontitis, including reduction in the frequency and severity of gingival inflammation occurrences, and significant decrease in the buildup of dental plaque and tartar. Delivery of Warfarin or its analogs directly to the oral fluid using toothpaste, mouthwash, chewing gum, dental floss, toothbrush, pill, and other forms are described to reduce chronic periodontitis, dental plaque, and dental tartar.

Claim (Index 6):
The method of  claim 1  wherein the vitamin K oxide-reductase inhibitor is introduced to the patient's oral fluid through mouthwash.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 93.0
- Lexical Diversity: 1.63934
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13258700', '15149044', '15108122', '10965694', '13529717']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7117255422312404
- 35 USC 102 Novelty (BERT): 0.4910455932864052
- Combined Prediction Score: 0.6896575473367569
- Mean Citation Score: 154.373074
- Max Citation Score: 167.16058
- Similarity Product: 107.5037626809263

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test